DOD, Spinal Cord Injury Research Program, Translational Research Award | W81XWH 22 SCIRP TRA

Opportunity Information: Apply for W81XWH 22 SCIRP TRA

The Department of Defense Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA), funding opportunity number W81XWH 22 SCIRP TRA, is designed to push spinal cord injury (SCI) discoveries out of the lab or early clinical observation stage and toward real-world clinical use. The program is specifically focused on translational work, meaning studies that take a promising idea and develop it far enough that it can realistically move into clinical applications such as a therapy, device, diagnostic approach, or practice guideline. The emphasis is on accelerating progress, so projects are expected to be more than basic science exploration and more than purely observational clinical work; they should clearly show how the research will bridge the gap between discovery and practical patient impact.

The types of projects the announcement highlights include demonstration studies of pharmaceuticals and medical devices in preclinical systems, as well as clinical research on therapeutics, devices, or clinical practices using human tissues or other human-based resources. In practical terms, this could mean preclinical studies that build a convincing evidence package for a candidate drug or device, or early clinical studies that evaluate feasibility, safety signals, or how a therapeutic approach performs in human-relevant settings. The goal is not limited to products alone; it also includes the clinical introduction of healthcare technologies or practice guidelines, so projects that lead to better standards of care or implementable clinical practices can also fit if they are genuinely translational and positioned to change clinical decision-making.

A key idea in the description is that translational research is not treated as a simple one-way pipeline from "bench to bedside." While many translational efforts start with a laboratory discovery, the program explicitly recognizes that clinically driven insights can be just as important. Research ideas may come from laboratory findings, population-based studies, or a clinician's firsthand experience with patients, including patterns noticed in routine care or even anecdotal observations that can be systematically tested. The program encourages a two-way exchange between basic and clinical science, where clinical findings can reshape lab experiments and lab results can refine clinical hypotheses. This reciprocal approach is meant to make the work more grounded in real patient needs and more likely to yield outcomes that can be adopted in practice.

Administratively, this is a discretionary funding opportunity offered by the Department of Defense, Department of the Army, through USAMRAA (U.S. Army Medical Research Acquisition Activity). The funding mechanisms include both grants and cooperative agreements, which typically signals that some awards may involve more active programmatic involvement from the funder (a common feature of cooperative agreements) depending on the project and how it is managed. The activity category is Science and Technology and other Research and Development, with CFDA number 12.420. Eligibility is listed as unrestricted, meaning it is broadly open to applicants across entity types, subject to any additional eligibility details that may be specified in the full announcement.

The opportunity was created on March 28, 2022, with an original closing date of September 2, 2022, and it anticipated making about five awards. The award ceiling is listed as 0, which usually indicates that the maximum award amount is not provided in the summary field and would need to be confirmed in the full funding announcement or related program guidance. Overall, the TRA is geared toward research teams that can demonstrate a clear and credible path to clinical application in SCI, ideally with a research plan that connects preclinical and clinical perspectives in a way that speeds up translation into tangible improvements for patients.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD, Spinal Cord Injury Research Program, Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 28, 2022.
• Applicants must submit their applications by Sep 02, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 SCIRP TRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: